Vaxart, Inc. (VXRT)
| Market Cap | 145.21M +26.0% |
| Revenue (ttm) | 255.61M +439.3% |
| Net Income | 37.10M |
| EPS | 0.16 |
| Shares Out | 241.97M |
| PE Ratio | 3.80 |
| Forward PE | 48.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 682,120 |
| Open | 0.5995 |
| Previous Close | 0.6200 |
| Day's Range | 0.5800 - 0.6200 |
| 52-Week Range | 0.2606 - 0.8449 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+399.92%) |
| Earnings Date | May 7, 2026 |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical... [Read more]
Financial Performance
Financial StatementsNews
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to V...
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Slides: Corporate presentation
Vaxart has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Vaxart Registration statement: Registration filing
Vaxart filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Vaxart Earnings Call Transcript: Q1 2026
Q1 saw strong revenue growth and positive net income, driven by BARDA contracts and cost controls. Key clinical milestones for COVID-19 and norovirus programs are pending, with cash runway into Q2 2027 and flexible capital options in place.
Vaxart Earnings release: Q1 2026
Vaxart released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Vaxart Quarterly report: Q1 2026
Vaxart has published its Q1 2026 quarterly earnings report on May 8, 2026.
Vaxart Registration statement: Registration filing
Vaxart filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second qua...
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company's s...
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based...
Vaxart Registration statement: Registration filing
Vaxart filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
Vaxart Transcript: Fireside chat
Management discussed progress on partnerships, clinical milestones, and cost-saving measures, emphasizing the oral vaccine platform's global potential and ongoing efforts to secure funding and partnerships. The team addressed delays, clarified operational changes, and outlined a cash runway into Q2 2027.